RxDoctor Payments Data

Joseph Micchia, DO

Family Medicine · Wake Forest, NCNPI 1699749408

Payments from drug & device makers

$904in general payments, 2019–2025

Across 36 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$325
  • Novo Nordisk$155
  • Amgen$150
  • Circassia Inc.$114
  • Lilly USA, LLC$60
  • Medtronic$34
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott10$325
Novo Nordisk13$155
Amgen3$150
Circassia Inc.1$114
Lilly USA, LLC3$60
Medtronic(2 entities)2$34
Astellas Pharma US Inc1$25
Genentech USA, Inc.1$16
Sonex Health, Inc.1$12
Merck1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,729
Medicare patients
208
Services billed
1,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$60,119
JardianceEmpagliflozin35$47,899
MounjaroTirzepatide43$46,592
RybelsusSemaglutide26$41,858
EliquisApixaban27$36,175
TrulicityDulaglutide27$31,156
XareltoRivaroxaban25$25,186
Breo ElliptaFluticasone/Vilanterol16$6,902
Atorvastatin Calcium484$5,084
Rosuvastatin Calcium292$3,273
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,871
Gabapentin110$2,507
Amlodipine Besylate424$2,461
Tamsulosin Hcl149$2,418
SynthroidLevothyroxine Sodium26$2,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$155$101,97784 claims
Lilly USA, LLCMounjaro, Trulicity$60$77,74870 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wake Forest

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →